Disease Domain | Count |
---|---|
Infectious Diseases | 14 |
Nervous System Diseases | 3 |
Neoplasms | 2 |
Hemic and Lymphatic Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 14 |
Inactivated vaccine | 4 |
Conjugated vaccine | 2 |
Genetically engineered subunit vaccine | 2 |
Live attenuated vaccine | 2 |
Top 5 Target | Count |
---|---|
HBsAg | 1 |
Target- |
Mechanism Immunostimulants |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date03 May 2023 |
Target- |
Mechanism Immunostimulants |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CA |
First Approval Date19 Oct 2017 |
Target- |
Mechanism Immunostimulants |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date13 Jan 2013 |
Start Date01 Sep 2023 |
Sponsor / Collaborator |
Start Date06 Oct 2021 |
Sponsor / Collaborator |
Start Date10 Sep 2021 |
Sponsor / Collaborator |